skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Sponsored by:

The Global Generics and Biosimilars Awards 2022 winners have been announced
Click here to view the winners

The Global Generics and Biosimilars Awards celebrate the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals. Co-locating with CPhI Worldwide in Frankfurt, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and Business Development of the Year.

KEY DETAILS
  • Ceremony 2 November 2022
  • Frankfurt Marriott Hotel, Germany

The Global Generics and Biosimilars Awards are free to enter. The closing date for entries is 19 August 2022, and the qualifying period for submissions is 1 July 2021 - 31 July 2022. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 2 November 2022.

The winners have been announced!

THE GLOBAL GENERICS & BIOSIMILARS AWARDS winners 2022

Download All

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.

WINNER:

  • Accord Healthcare

NOMINEES:

COMPANY OF THE YEAR

  • Accord Healthcare
  • Adalvo
  • Beximco Pharmaceuticals
  • Eurolab
  • Samsung Bioepis
  • Sandoz
  • Stada
  • West Pharmaceutical Services

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business. There are awards for the following regions: Americas / EMEA / Asia-Pacific.

WINNER:

COMPANY OF THE YEAR, AMERICAS

  • Dr. Reddy’s Laboratories - Americas

COMPANY OF THE YEAR, ASIA-PACIFIC

  • Samsung Bioepis

COMPANY OF THE YEAR, EMEA

  • Sandoz

NOMINEES:

COMPANY OF THE YEAR, AMERICAS

  • Amneal Pharmaceuticals
  • Coherus BioSciences
  • Dr. Reddy’s Laboratories - Americas
  • Eurofarma Laboratórios

COMPANY OF THE YEAR, ASIA-PACIFIC

  • Accord Healthcare Asia-Pacific
  • Beximco Pharmaceuticals
  • Piramal Pharma Solutions
  • Samsung Bioepis
  • Zydus Lifesciences

COMPANY OF THE YEAR, EMEA

  • Accord Healthcare
  • Biogen
  • Eurolab
  • Sandoz
  • Stada

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.

WINNER:

  • Beximco Pharmaceuticals

NOMINEES

  • Beximco Pharmaceuticals
  • Biogen and Bio-Thera Solutions
  • Biogen and Xbrane
  • Sandoz

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.

WINNER:

  • Richard Saynor - Chief Executive Officer, Sandoz

NOMINEES:

  • Alpha Indraccolo - Vice President and General Counsel, European IP and Regulatory Litigation, Teva Pharmaceuticals (Teva Europe)
  • Gabe Simaan - Chairman, Eurolab
  • Ian Henshaw - Global Head of Biogen Biosimilars, Biogen
  • Lynne du Toit - Chief Executive Officer, Eurolab
  • Mr. Hyoung Ki Kim - Vice Chairman and Chief Executive Officer, Celltrion Healthcare
  • Mr. Rabbur Reza - Chief Operating Officer, Beximco Pharma
  • Peter Goldschmidt - Chief Executive Officer, Stada
  • Richard Saynor - Chief Executive Officer, Sandoz

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.

WINNER:

  • Accord Healthcare

NOMINEES:

  • Accord Healthcare
  • Adalvo
  • Biogen
  • Dr. Reddy’s Laboratories
  • Stada
  • Zentiva

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.

WINNER:

  • Shanghai Henlius Biotech

NOMINEES:

  • Accord Healthcare
  • Dr Reddy's Laboratories
  • mabxience
  • Sandoz
  • Shanghai Henlius Biotech
  • Stada

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or Intermediates.

WINNER:

  • Centrient Pharmaceuticals

NOMINEES:

  • Centrient Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Piramal Pharma Solutions
  • R L Fine Chem

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.

WINNER:

  • Accord Healthcare

NOMINEES:

  • Accord Healthcare
  • Alvotech
  • Lambda Therapeutic Research
  • Mabxience
  • Samsung Bioepis
  • Sandoz
  • Stada
  • Zydus Lifesciences

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.

WINNER:

  • Accord Healthcare

NOMINEES:

  • Accord Healthcare
  • Adalvo
  • Samsung Bioepis
  • Sun Pharmaceutical Industries

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.

WINNER:

  • Eurofarma Laboratórios

NOMINEES:

  • Accord Healthcare
  • Act4Biosimilars
  • Adalvo
  • Biogen
  • Centrient Pharmaceuticals
  • Coripharma
  • Eurofarma Laboratórios
  • Zydus Lifesciences

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

This category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their approach to intellectual property and their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; obtaining intellectual property to protect their own products or processes; or ways in which legal strategies or IP approaches from different global jurisdictions have been used as a template elsewhere, showing the benefits of a coordinated international IP strategy.

WINNER:

  • Stada

NOMINEES:

  • Stada
  • Teva
  • Viatris

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract manufacturers, law firms and consultants.

WINNER:

  • Biosimilars Forum

NOMINEES:

  • Adalvo
  • Biosimilars Forum
  • Cardinal Health
  • Lambda Therapeutic Research
  • Olon Group
  • Pinsent Masons Global Life Sciences Team
  • Piramal Pharma Solutions
  • Rephine

Who can Enter

These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.

The Judges

Want to sponsor an award?

Sponsorship of the Global Generics & Biosimilars Awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.

Sponsor Opportunities

Headline Sponsor

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com

our 2022 sponsors

Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.

In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics.

Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. A well-integrated pharma company, Aurobindo Pharma features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports to over 150 countries across the globe

In 1977, biochemist Silvia Gold and doctor Hugo Sigman founded Insud Pharma, transforming their lifelong vocation into a robust, integrated, global business dedicated entirely to caring for people's health and wellbeing. Today, we are a pharmaceutical group with a track record spanning over 40 years and a footprint in more than 45 countries, led by Leandro and Lucas Sigman. Our overarching goal is to improve people's health all over the world, providing accessible, effective, safe, quality medicines through our various business units, underpinned by continuous investment in R&D and cutting-edge technology at all our centres.

Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.

The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.

Pharmawise is a leading boutique consulting firm focused on generic and biosimilar market expertise. Since 2006, we have conducted 150+ projects for leading financial institutions, generic and pharmaceutical companies, spanning:

  • due-diligence, acquisition screening and post-deal support
  • portfolio optimization and pipeline design or selection
  • mature brand strategy and life cycle management
  • product or portfolio in-licensing and out-licensing
  • quality, pharmacovigilance and regulatory audits
  • operational and supply chain optimization
  • product and process development
  • organizational design and culture
  • intellectual property and patents
  • strategy development

We match deep know-how and know-who to your generic or biosimilar needs: our project teams include highly knowledgeable experts with ~20 years executive experience and networks at successful global or local generic companies and leading management consulting firms in the above-mentioned areas.

SanaClis is a full-service Global CRO with a fully integrated clinical supply chain, thereby offering a comprehensive range of end-to-end services for clinical trials. SanaClis was founded in 2000 by seasoned industry experts, all of whom have had executive level positions in leading pharma companies and large global CROs.

SanaClis has vast experience of successfully running studies for various sized sponsors, ranging from virtual biotech’s through to top ten pharma companies, both in terms of its CRO services and Clinical supply services. Every project is a fundamental priority for the SanaClis, irrespective of the size or scope. SanaClis believes that every company and professional should receive an extremely high level of quality and clinical excellence applied to its projects. SanaClis prides itself upon its esteemed track record of successfully delivering various projects on time and on budget, ensuring quality, expertise and responsiveness resonates throughout the entire project duration.

Whilst SanaClis offers the provisions of our services across all therapeutic areas and geographic locations (entire Europe, UK, Asia and USA), SanaClis has a substantial and unique expertise in Central and Eastern European countries, regions of which provide an abundance of advantages, from high recruitment rates through to high quality of data. In addition to being a full service CRO, SanaClis is one of the very few service providers with an extensive range of in-house logistics and clinical supply capabilities. SanaClis has a portfolio of privately owned GMP and GDP certified storage and distribution depots, strategically located across the EU, US and further Eastern European countries.

CRO services include:

  • Project management
  • Regulatory
  • Monitoring
  • Data management and biostatistics
  • Medical writing
  • Pharmacovigilance

Further in-house supply chain services include:

  • QP services (EU QP release)
  • customs brokerage
  • warehousing and distribution (at all required temp conditions, ambient, cold, frozen, cryo etc)
  • sourcing of clinical trial materials (including ancillaries, PPE), comparator, generics and rescue medication sourcing.

This unique and fully comprehensive service offering allows SanaClis to streamline the entire project from end-to-end, thereby creating cost efficiencies, whilst maintaining a high level of quality at all times

STADA is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, we are perceived as a reliable and trustworthy partner for more than 125 years. With our products we help people protect and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop personally.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

our 2022 supporters

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.

In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.

PREVIOUS Global Generics & Biosimilars Award CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.

2021
GLOBAL GENERICS & BIOSIMILARS AWARDS 2021

November 10, 2021

2020
GLOBAL GENERICS & BIOSIMILARS AWARDS 2020

Virtual ceremony November 3, 2020

2019
GLOBAL GENERICS & BIOSIMILARS AWARDS 2019

November 5, 2019

got a question about the awards?

Please enter your name
Please enter your email
Please enter your valid email
Please enter your question
Please accept the terms & conditions
Senior Events Manager

jo.kirkpatrick@informa.com